146 References 307. Findling RL, Short EJ, Manos MJ. Developmental aspects <strong>of</strong> psychostimulant treatment in children <strong>and</strong> adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2001;40:1441–7. 308. Faraone SV, Pliszka SR, Olvera RL, Biederman J. Adderall <strong>and</strong> methylphenidate in ADHD. In 2001 Annual Meeting <strong>of</strong> <strong>the</strong> American Psychiatric Association, 5–10 May 2001, New Orleans, LA. 309. Faraone SV, Short EJ, Biederman J, Findling RL, Roe C, Manos MJ. Efficacy <strong>of</strong> Adderall <strong>and</strong> methylphenidate in attention deficit hyperactivity disorder: a drug–placebo <strong>and</strong> drug–drug response curve analysis <strong>of</strong> a naturalistic study. Int J Neuropsychopharmacol 2002;5:121–9. 310. Newcorn J, Spencer TJ, Biedermann J, Milton D, Michelson D. Atomoxetine treatment in children <strong>and</strong> adolescents with attention-deficit/hyperactivity disorder <strong>and</strong> comorbid oppositional defiant disorder. Indianapolis, IL: Eli Lilly <strong>and</strong> Company; 2004. 311. Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, et al. The link between health-related quality <strong>of</strong> life <strong>and</strong> clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004;25:166–74. 312. Dunn D, Michelson D, Allen AJ, Kelsey D, Wernicke JF. Once-daily atomoxetine treatment for children <strong>and</strong> adolescents with attentiondeficit/hyperactivity disorder. Ann Neurol 2002;52 (Suppl 3):S116. 313. Bukstein OG. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder symptoms in children <strong>and</strong> adolescents. Evid Based Ment Health 2003;6:42. 314. Michelson D. Once-daily administration <strong>of</strong> atomoxetine: a new treatment for ADHD. In 155th Annual Meeting <strong>of</strong> <strong>the</strong> American Psychiatric Association, 18–23 May 2002, Philadelphia, PA. 315. Michelson D, Buitelaar J, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Atomoxetine in <strong>the</strong> long-term prevention <strong>of</strong> relapse in ADHD. Eur Neuropsychopharmacol 2003;13 (Suppl 4):S455–6. 316. Pelham WE, H<strong>of</strong>fman MT, Lock T. Evaluation <strong>of</strong> once-a-day OROS methylphenidate HCI (MPH) extended-release tablets versus MPH tid in children with ADHD in natural school settings. Pediatr Res 2000;47:31A. 317. Pelham WE, H<strong>of</strong>fman MT, Lock T. Evaluation <strong>of</strong> once-a-day OROS ® methylphenidate HCl (MPH) extended-release tablets vs MPH tid in children with ADHD in a laboratory setting. Pediatr Res 2000;47:180. 318. Connor D. Once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with ADHD. Evid Based Ment Health 2002;5:20. 319. Pliszka SR, Wynne SK, Olvera RL, Browne RG. Comparing Adderall methylphenidate in ADHD. In 152nd Annual Meeting <strong>of</strong> <strong>the</strong> American Psychiatric Association, 15–20 May 1999, Washington, DC. 320. Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J. Efficacy <strong>of</strong> Adderall <strong>and</strong> methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug–placebo <strong>and</strong> drug–drug response curve methodology. J Child Adolesc Psychopharmacol 2001;11:171–80. 321. Law SF, Schachar RJ. Do typical clinical doses <strong>of</strong> methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999;38: 944–51. 322. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, et al. Dose-response effects <strong>of</strong> methylphenidate on ecologically valid measures <strong>of</strong> academic performance <strong>and</strong> classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol 2001;9:163–75. 323. Smith BH, Pelham WE, Jr., Gnagy E, Molina B, Evans S. The reliability, validity, <strong>and</strong> unique contributions <strong>of</strong> self-report by adolescents receiving treatment for attentiondeficit/hyperactivity disorder. J Consult Clin Psychol 2000;68:489–99. 324. Stein M, Seymour K, Black D, Sarampote C, Robb A, Conlon C, et al. Effects <strong>and</strong> side effects <strong>of</strong> Concerta methylphenidate (MPH) in children with ADHD <strong>and</strong> comorbid internalizing symptoms. Pediatr Res 2003;53:555A. 325. Wolraich ML. Efficacy <strong>and</strong> safety <strong>of</strong> OROS ® methylphenidate HCl (MPH) extended-release tablets (CONCERTA), conventional MPH, <strong>and</strong> placebo in children with ADHD. Int J Neuropsychopharmacol 2000;3 (Suppl 1):S329. 326. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. R<strong>and</strong>omized, controlled trial <strong>of</strong> OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:883–92.
This version <strong>of</strong> HTA monograph volume 10, number 23 does not include <strong>the</strong> 220 pages <strong>of</strong> appendices. This is to save download time from <strong>the</strong> HTA website. The printed version <strong>of</strong> this monograph also excludes <strong>the</strong> appendices. View/download <strong>the</strong> appendices (800 kbytes).
- Page 1 and 2:
A systematic review and economic mo
- Page 3 and 4:
A systematic review and economic mo
- Page 5 and 6:
Objectives: To assess the clinical
- Page 7 and 8:
Glossary and list of abbreviations
- Page 9 and 10:
Glossary Adverse effect An abnormal
- Page 11 and 12:
Glossary continued effects. Sometim
- Page 13 and 14:
Glossary continued point between tw
- Page 15 and 16:
Background Attention deficit hypera
- Page 17 and 18:
mean differences with 95% confidenc
- Page 19:
This review examines the clinical a
- Page 22 and 23:
4 Background E. Symptoms should not
- Page 24 and 25:
6 Background Concerta XL Concerta X
- Page 26 and 27:
8 Methods for reviewing effectivene
- Page 28 and 29:
10 Methods for reviewing effectiven
- Page 31 and 32:
Quantity and quality of research av
- Page 33 and 34:
TABLE 1 The quality of included stu
- Page 35 and 36:
TABLE 2 An overview of trials inclu
- Page 37 and 38:
TABLE 2 An overview of trials inclu
- Page 39 and 40:
TABLE 3 MPH low dose (≤15 mg/day)
- Page 41 and 42:
Quality of life Only one of the 12
- Page 43 and 44:
TABLE 5 MPH medium dose (15-30 mg/d
- Page 45 and 46:
Hyperactivity All nine studies that
- Page 47 and 48:
TABLE 6 Results for hyperactivity [
- Page 49 and 50:
Study Parallel trials Buitelaar 199
- Page 51 and 52:
TABLE 8 Results for hyperactivity [
- Page 53 and 54:
Study Parallel trials Gittelman-Kle
- Page 55 and 56:
TABLE 11 MPH high dose (>30 mg/day)
- Page 57 and 58:
TABLE 14 ER-MPH medium dose (20-40
- Page 59 and 60:
Study Crossover trials Stein 2003 S
- Page 61 and 62:
TABLE 19 Results for hyperactivity
- Page 63 and 64:
TABLE 22 MPH low dose (≤ 15 mg/da
- Page 65 and 66:
TABLE 24 MPH medium dose (15-30 mg/
- Page 67 and 68:
assessed by parents and teachers. I
- Page 69 and 70:
TABLE 27 Results for hyperactivity
- Page 71 and 72:
TABLE 30 DEX medium dose (10-20 mg/
- Page 73 and 74:
TABLE 33 Results for hyperactivity
- Page 75 and 76:
TABLE 38 DEX medium dose (10-20 mg/
- Page 77 and 78:
TABLE 41 DEX-SR plus non-drug inter
- Page 79 and 80:
Study Michelson 2001 [0.5] Michelso
- Page 81 and 82:
Hyperactivity Five trials (publishe
- Page 83 and 84:
TABLE 47 IR-MPH low-dose (≤ 15 mg
- Page 85 and 86:
STP. 77,78 Neither examined hyperac
- Page 87 and 88:
Adverse events No significant diffe
- Page 89 and 90:
did report that there were no signi
- Page 91 and 92:
Summary The one study in this categ
- Page 93 and 94:
showed persisting significant super
- Page 95 and 96:
easily rectified with dosage adjust
- Page 97 and 98:
Aim The aim of this chapter is to r
- Page 99 and 100:
only level of social disability tha
- Page 101 and 102:
did not include a ‘global’ HRQo
- Page 103 and 104:
might decrease but costs would be e
- Page 105 and 106:
1st line pharmacotherapy Response,
- Page 107 and 108:
TABLE 70 Data for weighted average
- Page 109 and 110:
The probabilistic results were used
- Page 111 and 112:
The review also uncovered a mis-ref
- Page 113 and 114: TABLE 77 Results of sensitivity ana
- Page 115 and 116: TABLE 80 Response a rates (%) estim
- Page 117 and 118: TABLE 82 Drug costs used in the cos
- Page 119 and 120: The review of the economic evidence
- Page 121 and 122: Extrapolation A secondary analysis
- Page 123 and 124: economic model rests on the assumpt
- Page 125 and 126: TABLE 87 Data used in calculating w
- Page 127 and 128: not fully probabilistic. The averag
- Page 129 and 130: Probability cost-effective 1.0 0.9
- Page 131 and 132: TABLE 93 Results of sensitivity ana
- Page 133 and 134: Base case model Responder to MPH Re
- Page 135 and 136: TABLE 96 Results of the sensitivity
- Page 137 and 138: The same method for synthesising th
- Page 139 and 140: TABLE 103 Results of the economic m
- Page 141: of the 64 identified in the clinica
- Page 144 and 145: 126 Discussion impact of active dru
- Page 147: MPH, DEX and ATX improve hyperactiv
- Page 151 and 152: 1. National Institute for Clinical
- Page 153 and 154: tutoring on the behavior and achiev
- Page 155 and 156: 91. Stein MA, Blondis TA, Schnitzle
- Page 157 and 158: 140. Hill P, Taylor E. An auditable
- Page 159 and 160: 189. Francis S, Fine J, Tannock R.
- Page 161 and 162: 235. Rhodes SM, Coghill DR, Matthew
- Page 163: hyperactive boys: comparative and c
- Page 167 and 168: 380 Health Technology Assessment Pr
- Page 169: 382 Health Technology Assessment Pr